

Toward the use of nanotechnology to enhance the therapeutic effect of nerolidol.

Rahaf Mousa Ahmad

Institute of Nanotechnology, Jordan University of Science and Technology, Irbid 22110, Jordan

Date of Submission: 10-12-2021

Revised: 20-12-2021

Date of Acceptance: 25-12-2021

ABSTRACT

Research and development in pharmaceutical chemistry have been ongoing for several decades, but the poor solubility of lipophilic compounds in aqueous media is a persistent barrier to their absorption, bioavailability, and effectiveness. Nanotechnology is highly emerging nowadays in different fields ranging from medicine to engineering. Using nanotechnology in drug delivery is a highly promising strategy to overcome such limitations and enhance the therapeutic effect of natural and chemical agents. Nerolidol which is a natural sesquiterpene is highly potent active ingredient, but its hydrophobicity is limiting its duration of action as well as its therapeutic effect. Using nanotechnology to enhance nerolidol activity was studied recently. Using different nanoparticles in encapsulating nerolidol or in functionalizing it was shown to improve its activity. Agents with similar chemical structures were successfully delivered using different carriers but were not implemented to deliver nerolidol. This review aims to compare between different nano formulations that were previously studied to deliver nerolidol and suggest other nano formulations to be developed in the future.

Keywords: Nerolidol, Nanotechnology, Drug delivery, Hydrophobic.

I. BACKGROUND

The knowledge and use of materials at dimensions between 1 and 100 nm are known as nanotechnology. Materials at the nanoscale can be devices, systems, structures, complexes, or composites. In fact, the physical and chemical

properties of materials can change as their size is down scaled into smaller clusters which results in higher surface area to volume ratio and enormous percentage of atoms on the surface when compared their bulk origin. This has opened exciting new possibilities to solve great challenges in several areas, such as energy, environment, medicine and biology(1,2). Nanosized carriers overcome the limitations of traditional DD methods, leading to improved therapies for various diseases (3).

Hydrophobicity and oral drug delivery

Hydrophobic drugs are drugs having poor water solubility. Those drugs are not easy to be formulated using traditional known formulating approaches due to their problems including slow onset of action, bioavailability is poor following oral administration, lack of achieving steady state plasma concentration, and even unwanted side effects. Such drugs will result in higher or lower dose of the drug reaching the blood and poor patient compliance(4).

Nerolidol

Nerolidol (3,7,11-trimethyl-1, 6, 10-dodecatrien-3-ol), which is also called peruvicol, is a sesquiterpene alcohol that occurs naturally in the essential oils of several plants with floral odors including *Baccharis dracunculifolia*(5,6). has methyl groups at the carbon positions 3, 7 and 11 and a hydroxy group at position 3 as shown below in **Error! Reference source not found.** Chemically, two geometric isomers of NR are available, trans and cis forms. It is a farnesane sesquiterpenoid, a tertiary allylic alcohol and a volatile organic compound(5-7).




Figure 1: chemical structure of trans-Nerolidol

NR is still being explored by researchers, yet there is no definite dose of NR to be used, but up to 500 mg/kg of NR was proven to be safe during research on animals but to most common dose used is 200 mg/kg. NR was successfully given orally and intra-peritoneally in animals (8,9).

Effects of nerolidol

The effect of NR has been investigated and it was shown to have protective effects in different conditions and organs such as the heart and kidneys(10–12). Moreover, NR was shown to have anti-ulcer (7), anti-inflammatory (13,14), anti-Trypanosoma(15,16), anti-fungal (17,18), anti-malarial (19,20), anti-tumor (21,22) and skin permeation enhancing effects (23,24). Nerolidol was shown to have an antinociceptive activity with possible involvement of the GABAergic system, and anti-inflammatory activity, which attributed to the suppression of tumor necrosis factor-alpha (TNF- α) and interleukin-1 β (IL-1 β) proinflammatory cytokines in peritoneal inflammation (25). Nerolidol was also shown to have an antimicrobial activity against Staphylococcus Aureus, Candida Albicans and Escherichia Coli (26). Nerolidol was found to have an antioxidant effect via free radicals scavenging and lipid peroxidation inhibition which were effective in neuroprotection against Parkinson's disease(27,28). Moreover, nerolidol was shown to attenuate the loss of cardiac functions following hypertension-induced inflammation in acute cases(10). Nerolidol also was reported to have a reno protective effect in lipopolysaccharide (LPS)-induced AKI, it reduced the pathological injury, blood urea nitrogen (BUN) and creatinine (Cr) and inhibited the increase of TNF- α and IL-1 β in LPS

treated rats (11). In a thioacetamide induced kidney injury, nerolidol was shown to ameliorate oxidative damage in kidney tissue (12). Although nerolidol was found to be therapeutically effective in all previously mentioned areas, this effect was not with the full potency of nerolidol. This is due to the water in-solubility which leads to low plasma concentration and short circulation time.

Advantages of nanoscale drug delivery systems

The aim of nanotechnology in targeted DD and CR is to manage drug pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity and biorecognition of systems in the quest for improved efficacy in an improved manner. Nanoscale DD systems are considered powerful tools for imaging, diagnosis, and therapy due to their intrinsic properties (24). The intrinsic properties of nanomaterials include (26): ability to go through tiny capillary vessels due to their nano volume thus avoiding rapid clearance by phagocytes in the body and prolonging their availability in the blood stream, easily penetrate cells and tissue gaps to arrive at target organs such as the liver, kidneys, spleen, lungs, spinal cord and lymph glands, ability to demonstrate controlled-release properties using biodegradability, pH, ion and temperature sensibility of materials, and the ability to improve the utility of drugs and reduce undesired side effects.

Nano-formulations of nerolidol

NR functionalized gold nano particles (NR-AuNPs) by the reduction of chloroauric acid was successfully synthesized by Y. Jing, et al, and the results have shown an enhanced diabetic wound healing within a time of 14 days when compared to control group which took longer wound healing time upon topical application. This synthesis

process is considered environment friendly, this is due to the use of natural products as reducing agents(29). Baldissera et al has synthesized NSs loaded with NR using Eudragit polymer, the NSs was prepared according to the interfacial deposition of preformed polymer. These NPs were evaluated for their antimicrobial effect against *T. evansi* infected mice for oxidative stress, Na⁺, K⁺-ATPase and acetyl- cholinesterase (AChE) activities in brain tissue and *S. agalactiae* in the brain tissue of fish. Oral administration of NR-loaded NSs was able to reverse memory impairment, to prevent increased ROS and TBARS levels due to amelioration of Na⁺, K⁺-ATPase and AChE activities, protect the liver from the oxidative stress caused by *T. evansi*, activate the antioxidant enzymes, and increase the survival rates after *T. evansi* infection due to the enhanced therapeutic effect.

Therefore, nanoencapsulation increased the therapeutic efficacy of NR against *T. evansi* and can be used as an alternative treatment for *T. evansi* infection. The treatment also had potent bactericidal effects in terms of augmentation of fish longevity and survival, and reduction of brain microbial loads and against *S. agalactiae*-induced brain oxidative damage that contributed to disease pathogenesis(26,30–32).

El-hammadi et al, has successfully encapsulated NR in PLGA NPs using the nanoprecipitation and emulsion-solvent evaporation method, the formed NPs encapsulation efficiency was 55% and the therapeutic effect was enhanced (33). Nano-encapsulated NR inhibited neutrophils migration into joint cavity more efficiently compared with pure NR and control group by Barros silva et al. This was histological proved to have an improved anti-inflammatory effect on arthritis in mice by the quantification of pro-inflammatory and anti-inflammatory cytokines (34). Iqbal et al has developed nano-lipid carrier loaded NR dosage form which exerted significant neuroprotection compared to free NR. Due to its reduced particle size, it effectively crossed the blood brain barrier, increased its availability in the hippocampus and cortex and thus displayed neuroprotection treatment in a cyclophosphamide injury model in mice (35).

Future recommendations

Using biodegradable polysaccharides for the encapsulation of nerolidol was not previously investigated. Chitosan is a promising polysaccharide that was successfully used to encapsulate insulin for oral drug delivery(36).

Therefore, using such a delivery system seems to be effective.

II. CONCLUSION

In conclusion, nerolidol is a natural product with high potency of different therapeutic effects. Unfortunately, due to the hydrophobicity of nerolidol, its therapeutic effect was short acting and with low potency. The encapsulation of nerolidol in nanoparticles, or the functionalization of nerolidol with different nanoparticles is a promising approach for targeting sites of action, extending residence and release time, and increasing its bioavailability which in turn increases its therapeutic effect. Thus, the therapeutic effect of the drug is enhanced, and the side effects are minimized.

REFERENCES

- [1]. Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, et al. Therapeutic efficacy of nanoparticles and routes of administration. *Biomater Res.* 2019;23(1):1–29.
- [2]. Fornara A. Multifunctional nanomaterials for diagnostic and therapeutic applications Stockholm 2010 Division of Functional Materials. 2010. 169 p.
- [3]. Yhee JY, Son S, Kim N, Choi K, Kwon IC. Theranostic applications of organic nanoparticles for cancer treatment. *MRS Bull.* 2014;39(3):239–49.
- [4]. Patwekar SL, Baramade MK. CONTROLLED RELEASE APPROACH TO NOVEL MULTIPARTICULATE DRUG DELIVERY SYSTEM. 2012;4(3).
- [5]. Lapczynski A, Bhatia SP, Letizia CS, Api AM. Fragrance material review on nerolidol (isomer unspecified). *Food Chem Toxicol [Internet].* 2008;46(11 SUPPL.):S247–50. Available from: <http://dx.doi.org/10.1016/j.fct.2008.06.063>
- [6]. Ferreira FM, Palmeira CM, Oliveira MM, Santos D, Simões AM, Rocha SM, et al. Nerolidol effects on mitochondrial and cellular energetics. *Toxicol Vitr [Internet].* 2012;26(2):189–96. Available from: <http://dx.doi.org/10.1016/j.tiv.2011.11.009>
- [7]. Parreira NA, Magalhães LG, Morais DR, Caixeta SC, De Sousa JPB, Bastos JK, et al. Antiprotozoal, schistosomicidal, and antimicrobial activities of the essential oil from the leaves of *baccharis dracunculifolia*. *Chem Biodivers.* 2010;7(4):993–1001.
- [8]. Saito AY, Sussmann RAC, Kimura EA, Cassera MB, Katzin AM. Quantification of

- nerolidol in mouse plasma using gas chromatography-mass spectrometry. *J Pharm Biomed Anal* [Internet]. 2015;111:100–3. Available from: <http://dx.doi.org/10.1016/j.jpba.2015.03.030>
- [9]. He YS, Sun W, Zhang BY, Xu LH, Yang J, Gao W, et al. Application of a sensitive liquid chromatography-mass spectrometry method to a pharmacokinetic study of nerolidol in rat plasma. *Anal Methods* [Internet]. 2016;8(4):785–9. Available from: <http://dx.doi.org/10.1039/C5AY02575C>
- [10]. Asaikumar L, Vennila L, Akila P, Sivasangari S, Kanimozhi K, Premalatha V, et al. Preventive effect of nerolidol on isoproterenol induced myocardial damage in Wistar rats: Evidences from biochemical and histopathological studies. *Drug Dev Res*. 2019;80(6):814–23.
- [11]. Zhang L, Sun D, Bao Y, Shi Y, Cui Y, Guo M. Nerolidol Protects Against LPS-induced Acute Kidney Injury via Inhibiting TLR4/NF- κ B Signaling. *Phyther Res*. 2017;31(3):459–65.
- [12]. Türkmen NB, Yüce H, Çetin A, Şahin Y, Ciftci O. The Ameliorate Effects of Nerolidol on Thioastamide-Induced Oxidative Damage in Heart and Kidney Tissue. *Turkish J Pharm Sci*. 2021;0(0):0–0.
- [13]. Pinheiro BG, Silva ASB, Souza GEP, Figueiredo JG, Cunha FQ, Lahlou S, et al. Chemical composition, antinociceptive and anti-inflammatory effects in rodents of the essential oil of *Peperomia serpens* (Sw.) Loud. *J Ethnopharmacol* [Internet]. 2011;138(2):479–86. Available from: <http://dx.doi.org/10.1016/j.jep.2011.09.037>
- [14]. Lima DKS, Ballico LJ, Rocha Lapa F, Gonçalves HP, De Souza LM, Iacomini M, et al. Evaluation of the antinociceptive, anti-inflammatory and gastric antiulcer activities of the essential oil from *Piper aleyreanum* C.DC in rodents. *J Ethnopharmacol*. 2012;142(1):274–82.
- [15]. Nibret E, Wink M. Trypanocidal and antileukaemic effects of the essential oils of *Hagenia abyssinica*, *Leonotis ocymifolia*, *Moringa stenopetala*, and their main individual constituents. *Phytomedicine* [Internet]. 2010;17(12):911–20. Available from: <http://dx.doi.org/10.1016/j.phymed.2010.02.009>
- [16]. Hoet S, Stévigny C, Hérent MF, Quetin-Leclercq J. Antitrypanosomal compounds from the leaf essential oil of *Strychnos spinosa*. *Planta Med*. 2006;72(5):480–2.
- [17]. Lee SJ, Han JI, Lee GS, Park MJ, Choi IG, Na KJ, et al. Antifungal effect of eugenol and nerolidol against *Microsporum gypseum* in a guinea pig model. *Biol Pharm Bull*. 2007;30(1):184–8.
- [18]. Curvelo JAR, Marques AM, Barreto ALS, Romanos MTV, Portela MB, Kaplan MAC, et al. A novel nerolidol-rich essential oil from *Piper clausenianum* modulates *Candida albicans* biofilm. *J Med Microbiol*. 2014;63(PART 5):697–702.
- [19]. Goulart HR, Kimura EA, Peres VJ, Couto AS, Duarte FAA, Katzin AM. Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in *Plasmodium falciparum*. *Antimicrob Agents Chemother*. 2004;48(7):2502–9.
- [20]. Lopes NP, Kato MJ, Andrade EHDA, Maia JGS, Yoshida M, Planchart AR, et al. Antimalarial use of volatile oil from leaves of *Virola surinamensis* (Rol.) Warb. by Waiapi Amazon Indians. *J Ethnopharmacol*. 1999;67(3):313–9.
- [21]. Boris R, Elena T, Erich S, Walter J, Gerhard B, Leopold J. Cytotoxic properties of selected sesquiterpene alcohols on human cervix carcinoma cell lines. *J Essent Oil-Bearing Plants*. 2011;14(3):316–9.
- [22]. Samples SA. Natural Product Communications Investigation of Anticancer and Antiviral Properties of. 2008;
- [23]. Prasanthi D, Lakshmi PK. Terpenes: Effect of lipophilicity in enhancing transdermal delivery of alfuzosin hydrochloride. *J Adv Pharm Technol Res*. 2012;3(4):216–23.
- [24]. CORNWELL PA, BARRY BW. Sesquiterpene Components of Volatile Oils as Skin Penetration Enhancers for the Hydrophilic Permeant 5-Fluorouracil. *J Pharm Pharmacol*. 1994;46(4):261–9.
- [25]. Melekoglu R, Ciftci O, Eraslan S, Cetin A, Basak N. The beneficial effects of nerolidol and hesperidin on surgically induced endometriosis in a rat model*. *Gynecol Endocrinol* [Internet]. 2018;34(11):975–80. Available from: <https://doi.org/10.1080/09513590.2018.1469611>
- [26]. Baldissera MD, Souza CF, Grando TH, Moreira KLS, Schafer AS, Cossetin LF, et al. Nerolidol-loaded nanospheres prevent behavioral impairment via ameliorating Na⁺, K⁺-ATPase and AChE activities as well as reducing oxidative stress in the brain of *Trypanosoma evansi*-infected mice.

- Naunyn Schmiedebergs Arch Pharmacol [Internet]. 2017;390(2):139–48. Available from: <http://dx.doi.org/10.1007/s00210-016-1313-8>
- [27]. Kaur D, Pahwa P, Goel RK. Protective Effect of Nerolidol Against Pentylentetrazol-Induced Kindling, Oxidative Stress and Associated Behavioral Comorbidities in Mice. *Neurochem Res* [Internet]. 2016;41(11):2859–67. Available from: <http://dx.doi.org/10.1007/s11064-016-2001-2>
- [28]. Nogueira Neto JD, De Almeida AAC, Da Silva Oliveira J, Dos Santos PS, De Sousa DP, De Freitas RM. Antioxidant effects of nerolidol in mice hippocampus after open field test. *Neurochem Res*. 2013;38(9):1861–70.
- [29]. Yu, Jing; Wang, Xueting; Li, Ying; Huang, Xue; Luo, Xiaotong; He X. Synthesis of Nerolidol Functionalized Gold Nanoparticles for Wound Regeneration in People with Diabetic Foot Ulcers in Nursing Care Management. *Sci Adv Mater*. 2018;10(12).
- [30]. Baldissera MD, Grando TH, Souza CF, Cossetin LF, Ana PT, Dalla DF, et al. Experimental Parasitology Nerolidol nanospheres increases its trypanocidal efficacy against *Trypanosoma evansi*: New approach against diminazene aceturate resistance and toxicity. 2016;166:144–9.
- [31]. Baldissera MD, Souza CF, Grando TH, Dolci GS, Cossetin LF, Moreira KLS, et al. Nerolidol-loaded nanospheres prevent hepatic oxidative stress of mice infected by *Trypanosoma evansi*. *Parasitology*. 2017;144(2):148–57.
- [32]. Baldissera MD, Souza CF, da Silva AS, Velho MC, Ourique AF, Baldisserotto B. Benefits of nanotechnology: Dietary supplementation with nerolidol-loaded nanospheres increases survival rates, reduces bacterial loads and prevents oxidative damage in brains of Nile tilapia experimentally infected by *Streptococcus agalactiae*. *Microb Pathog* [Internet]. 2020;141(January):103989. Available from: <https://doi.org/10.1016/j.micpath.2020.103989>
- [33]. El-Hammadi MM, Small-Howard AL, Fernández-Arévalo M, Martín-Banderas L. Development of enhanced drug delivery vehicles for three cannabis-based terpenes using poly(lactic-co-glycolic acid) based nanoparticles. *Ind Crops Prod*. 2021;164(March).
- [34]. Barros Silva Soares de Souza EP, Trindade G das GG, Lins Dantas Gomes MV, Santos Silva LA, Grespan R, Quintans Junior LJ, et al. Anti-inflammatory effect of nano-encapsulated nerolidol on zymosan-induced arthritis in mice. *Food Chem Toxicol* [Internet]. 2020;135(October):110958. Available from: <https://doi.org/10.1016/j.fct.2019.110958>
- [35]. Iqbal A, Syed MA, Najmi AK, Azam F, Barreto GE, Iqbal MK, et al. Nano-engineered nerolidol loaded lipid carrier delivery system attenuates cyclophosphamide neurotoxicity – Probable role of NLRP3 inflammasome and caspase-1. *Exp Neurol* [Internet]. 2020;334(April):113464. Available from: <https://doi.org/10.1016/j.expneurol.2020.113464>
- [36]. Diop M, Auberval N, Viciglio A, Langlois A, Bietiger W, Mura C, et al. Design , characterisation , and bioefficiency of insulin – chitosan nanoparticles after stabilisation by freeze-drying or cross-linking. *Int J Pharm* [Internet]. 2015; Available from: <http://dx.doi.org/10.1016/j.ijpharm.2015.05.065>